Characteristics | |
---|---|
Sex: Male/Female | 17/14 |
Age (years) | |
Median | 60 |
Range | 24-81 |
WHO Performance status, n(%) | |
0 | 10 (32) |
1 | 16 (52) |
2 | 4 (13) |
3 | 1 (3) |
Primary tumor location, n (%) | |
Colon | 23 |
Rectum | 8 |
Metastatic sites, n (%) | |
Liver | 26 (84) |
Lung | 13 (42) |
Peritoneum | 5 (16) |
Others | 12 (39) |
Number of metastatic sites, n (%) | |
1 | 15 (48) |
2 | 10 (32) |
≥ 3 | 7 (23) |
Chemotherapy associated with bevacizumab, n (%) | |
FOLFIRI | 19 (61) |
FOLFOX4 | 12 (39) |
Line number of bevacizumab, n (%) | |
2nd line | 1(3.25) |
3rd line | 10 (32.25) |
4th line | 10 (32.25) |
5th or later-line | 10 (32.25) |
Previous chemotherapy | |
Fluoropyrimidine + irinotecan + oxaliplatin | 27 |
Fluoropyrimidine + irinotecan | 3 |
Fluoropyrimidine + oxaliplatin | 1 |
Cetuximab | 19 |